On January 30, 2026, Eli Lilly announced plans to invest over $3.5 billion in a state-of-the-art injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. This site marks the final of four new plants promised under the “Lilly in America” initiative to bolster domestic production capacity.
Project Highlights:
-
Strategic Location: The facility will be situated in Fogelsville, Lehigh County, Pennsylvania. This site was selected from over 300 applications due to its proximity to premier STEM universities and a robust technical manufacturing infrastructure.
-
Core Production Focus: The plant will specialize in injectables and medical devices, with a specific focus on next-generation weight-loss therapies. A primary focus is retatrutide, an investigational triple-hormone receptor agonist that has demonstrated significant weight-loss efficacy in late-stage clinical trials.
-
Economic Impact and Employment: The project is expected to create 850 high-value jobs (engineers, scientists, and technicians) and approximately 2,000 construction jobs. Pennsylvania has committed $100 million in incentives and tax credits to support this historic investment.
-
Advanced Technology: The site will integrate cutting-edge technologies, including Artificial Intelligence (AI), machine learning, and advanced data analytics, to ensure manufacturing excellence.
Investment Context: The Pennsylvania facility completes a quartet of new U.S. plants announced over the past year, joining sites in Virginia, Texas, and Alabama. These four projects represent a $27 billion investment commitment, driven by surging global demand for weight-loss drugs (GLP-1) and a strategic shift toward domestic supply chain resilience amidst tariff pressures. Construction is slated to begin this year, with the facility expected to be operational by 2031.